Y Intercept Hong Kong Ltd Has $1.59 Million Holdings in Healthpeak Properties, Inc. $DOC

Y Intercept Hong Kong Ltd increased its holdings in Healthpeak Properties, Inc. (NYSE:DOC) by 79.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,933 shares of the real estate investment trust’s stock after buying an additional 36,609 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Healthpeak Properties were worth $1,588,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in DOC. Mather Group LLC. acquired a new position in Healthpeak Properties in the 3rd quarter valued at $25,000. City Holding Co. bought a new position in shares of Healthpeak Properties in the third quarter worth $26,000. Sound Income Strategies LLC acquired a new position in Healthpeak Properties in the third quarter valued at about $28,000. Rexford Capital Inc. bought a new stake in Healthpeak Properties during the second quarter worth about $28,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Healthpeak Properties during the second quarter worth about $32,000. 93.57% of the stock is currently owned by institutional investors.

Healthpeak Properties Stock Performance

NYSE DOC opened at $17.22 on Friday. The firm’s fifty day moving average price is $17.00 and its two-hundred day moving average price is $17.66. The stock has a market cap of $11.97 billion, a PE ratio of -344.33, a PEG ratio of 4.32 and a beta of 1.12. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.22 and a current ratio of 1.22. Healthpeak Properties, Inc. has a fifty-two week low of $15.71 and a fifty-two week high of $21.28.

Healthpeak Properties Announces Dividend

The company also recently announced a monthly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 17th will be given a $0.1017 dividend. The ex-dividend date is Tuesday, March 17th. This represents a c) annualized dividend and a yield of 7.1%. Healthpeak Properties’s dividend payout ratio (DPR) is currently -2,440.00%.

Analysts Set New Price Targets

Several brokerages have recently commented on DOC. Wells Fargo & Company boosted their target price on shares of Healthpeak Properties from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 25th. Weiss Ratings upgraded shares of Healthpeak Properties from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday. Jefferies Financial Group downgraded Healthpeak Properties from a “buy” rating to a “hold” rating and reduced their target price for the company from $21.00 to $17.00 in a report on Monday, December 15th. Robert W. Baird decreased their price target on Healthpeak Properties from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 12th. Finally, Evercore ISI dropped their price objective on Healthpeak Properties from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Healthpeak Properties has an average rating of “Hold” and a consensus target price of $19.67.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.